NASDAQ: FLNAFilana Therapeutics Inc Stock
$0.66+0.01 (+1.54%)
Updated Oct 29, 2026
FLNA Price
$0.66
Fair Value Price
N/A
Market Cap
$31.79M
52 Week Low
$0.60
52 Week High
$3.45
P/E
-0.76x
P/B
0.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.63
Operating Cash Flow
-$29M
Beta
1.19
Next Earnings
Nov 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FLNA Overview
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FLNA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FLNA
Ranked#270 of 451
Ranked#270 of 451
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.54 | A | |
| $371.56 | A | |
| $10.95 | A |
Be the first to know about important FLNA news, forecast changes, insider trades & much more!
FLNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FLNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FLNA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FLNA is good value based on its book value relative to its share price (0.5x), compared to the US Biotechnology industry average (5.21x)
P/B vs Industry Valuation
FLNA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FLNA due diligence checks available for Premium users.
Valuation
FLNA fair value
Fair Value of FLNA stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$1.98
Undervalued by
66.62%
FLNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FLNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
15.06x
Market
47.98x
FLNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
5.21x
FLNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FLNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.6M
Profit Margin
0%
FLNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$103.9M
Liabilities
$40.3M
Debt to equity
0.63
FLNA's short-term assets ($83.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FLNA's short-term assets ($83.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FLNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FLNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$0.0
Financing
-$16.0k
FLNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FLNA vs Biotech Stocks
Filana Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.